Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
United Therapeutics (UTHR) · oqro.io/stocks/UTHR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about United Therapeutics insider trading
Have United Therapeutics insiders bought shares recently?
No open-market purchase by an insider of United Therapeutics was filed in the last 90 days. The latest on record was on Jun 10, 2019.
How often do United Therapeutics insiders buy and sell shares?
Since 2005, United Therapeutics insiders reported 43 open-market purchases and 8,358 sales on Forms 4 and 5, with purchases in 6 different years, most recently 2019.
Who is selling United Therapeutics stock?
In the last 90 days, 3 insiders of United Therapeutics (UTHR) reported more than 200 open-market sales on SEC Form 4. The largest seller by value was Martine A Rothblatt, with $180M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade UTHR?
Yes. Members of Congress disclosed 3 trades in United Therapeutics (UTHR) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Lisa C. McClain (MI09).
When does United Therapeutics report its next results?
United Therapeutics's next results are expected on Feb 23, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+16.9% (+$80.01) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $474.72 on Nov 20, 2025 to $554.73 on Nov 20, 2026 (+16.9%). Disclosed in this range: 3 insider trades, 997 pre-arranged insider sales, 0 Congress trades, and 48 13F position changes for 4 quarters ending in it.
$450$500$600$650$554.73
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast. Only the 1,000 most recent trades are drawn.Show the 1,000 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company.
Last 12 months
+17.3%
S&P 500 +8.0% over the same dates
Market value
$23.8B
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.84M shares sold short (4.3% of shares outstanding), −25.2% vs the previous count, 3.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$833M
+4.1% vs the same quarter a year earlier
Free cash flow, last 12 months
$867M
This quarter $126M, a year earlier $352M
Net debt
—
Debt —, cash $1.19B, at Sep 30, 2026
Net income, last 12 months
$1.23B
Operating profit covers interest 111x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2005
Insiders of United Therapeutics reported 43 open-market purchases and 8,358 sales since 2005; purchases in 6 different years, most recently 2019.
Year
Bought
Sold
2026
—
$1.28B2723×2,723 trades
2025
—
$494M705×705 trades
2024
—
$333M1009×1,009 trades
2023
—
$195M559×559 trades
2022
—
$140M422×422 trades
2021
—
$19.2M41×41 trades
2020
—
$47.6M135×135 trades
2019
$3311×1 trade
$18.2M62×62 trades
2018
$6841×1 trade
$32.8M62×62 trades
2017
$1.4K3×3 trades
$10.4M115×115 trades
2016
—
$23.2M193×193 trades
2015
—
$176M757×757 trades
2014
—
$191M444×444 trades
2013
—
$69.8M246×246 trades
2012
$2.98M18×18 trades
$24.4M46×46 trades
2011
$3.75M16×16 trades
$66.5M126×126 trades
2010
—
$102M207×207 trades
2009
$8.33M4×4 trades
$18.4M46×46 trades
2008
—
$53.8M173×173 trades
2007
—
$41.4M140×140 trades
2006
—
$29.4M145×145 trades
2005
—
$576K2×2 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last 30 days
Written by software from the filings listed below · Nov 18, 2026
Insiders. In the 30 days to Nov 18, 2026, insiders filed 317 open-market sales (about $122M, in 26 filings, by 3 people) United Therapeutics on OQRO. The largest sale was by Martine A Rothblatt, Chairperson & CEO, about $1.83M, filed Nov 13, 2026 Largest sale, Nov 13, 2026.
4 more points, with the facts they come from, are in OQRO Pro.
Since Nov 18, 2025, UTHR is up 17.3% and the index fund is up 8.5%: 9 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much UTHR moves
A usual day
±1.0%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
3.3%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−7.0%Nov 5, 2026
Largest one-day rise
+13.0%Feb 25, 2026
Deepest fall of the year
−20.9%From the close of May 6, 2026 to Sep 24, 2026.
Days of 5% or more
8Out of 252 sessions, in either direction.
Beta 0.5(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
Owners above 5%
Latest filing Nov 4, 2026
Nobody is above 5% on the latest filings: every recent filer has reported going below the line.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
4 active phase 3 trials and 3 active phase 2 trials led by this company, mostly in pulmonary hypertension associated with chronic obstructive pulmonary disease, esrd (end-stage renal disease), pah. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 20, 2026
Insiders. Insiders filed 2,933 open-market sales (about $1.44B) in 298 filings by 12 people. Michael Benkowitz made the largest sale of about $7.35M, filed Dec 31, 2025. Link
Congress. Members filed 3 disclosures: 1 purchase and 2 sales by 1 member. Rep. Lisa C. McClain had the largest range of $1,001 to $15,000, filed Nov 21, 2025. Link
Funds and stakes. 13F filings show 24 new or larger positions and 24 smaller or closed positions. Martine A. Rothblatt cut its UTHR stake below 5% (4%), filed Nov 4, 2026. Link
Contracts, lobbying and filings. The company received 10 federal contract awards with about $391K obligated. FINRA short interest was 1,837,654 shares on Oct 30, 2026. Link
Company reports, price and press. UTHR closed at $559.10 on Nov 19, 2026. The share price rose 12.6% on Sep 30, 2026, closing at $541.89. Link
Who holds it. 877 funds reported a stake in Q2 2026. BlackRock, Inc. held the largest value at 12.7%, followed by Avoro Capital Advisors LLC at 6.6%. Link
Things to keep in mind. These are counts of filings OQRO holds on the days they were filed. A filing or headline published around a price move is not proof that it caused the move.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. A language model worded it.
Insiders
In the 12 months to Nov 20, 2026, insiders of United Therapeutics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 2,933 open-market sales (about $1.44B, in 298 filings, by 12 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 610 open-market sales (about $369M, in 92 filings).
The largest sale: Michael Benkowitz, PRESIDENT AND COO, about $7.35M, filed Dec 31, 2025.
Congress
Members of Congress filed 3 disclosures on United Therapeutics in the 12 months to Nov 20, 2026: 1 purchase and 2 sales, by 1 member. In the 12 months before that: 1 disclosure.
The largest range: Rep. Lisa C. McClain (MI09), $1,001 to $15,000, filed Nov 21, 2025.
Funds and stakes
Fund 13F filings recorded in the 12 months show 24 new or larger positions and 24 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Martine A. Rothblatt cut its UTHR stake below 5% (4%) (filed Nov 4, 2026).
Contracts, lobbying and filings
10 federal contract awards to the company were recorded in the 12 months, with about $391K obligated so far. A contract amount is what the agency obligated, not revenue.
ClinicalTrials.gov shows 7 studys sponsored by the company updated in the period; the latest, "An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertensio..." (Phase 2/3, status not yet recruiting), was updated on Nov 6, 2026, with primary completion listed for 2034-09.
FINRA short interest for UTHR on the settlement date of Oct 30, 2026 was 1,837,654 shares (-25.23% on the previous report), about 3.45 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 14,068 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $18M for its principal executive officer, and an average of $9.42M for the other named executive officers.
Company reports, price and press
United Therapeutics filed a Form 8-K on Jul 23, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
United Therapeutics filed a Form 8-K on Jun 29, 2026 (Items 5.02, 5.07) that OQRO classes as: changed a top executive or board member, and held a shareholder vote.
The company's own opening sentence of that report reads: "As described in Item 5.07 below, on June 26, 2026, at the 2026 Annual Meeting of Shareholders of United Therapeutics Corporation (the Company ), the Company’s shareholders approved the United Therapeutics Corporation 2026 Stock I..."
United Therapeutics filed a Form 8-K on Jan 22, 2026 (Items 5.02, 5.03, 7.01) that OQRO classes as: changed a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item).
United Therapeutics's share price rose 12.6% on Sep 30, 2026 (close $541.89, from $481.47), about 10 times its usual one-session change.
UTHR closed at $559.10 on Nov 19, 2026, the last session on or before the end of the period.
From Oct 20, 2026 to Nov 19, 2026, the close moved from $553.88 to $559.10, a change of +0.9%.
Who holds it
877 funds reported a stake in United Therapeutics in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (12.7% of the value reported), Avoro Capital Advisors LLC (6.6% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (4.6% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
A filing or headline published around a price move is not proof that it caused the move; OQRO lists it as published.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 25, 2026. Read the filing
By product or service
Tyvaso DPI$1.29B41%
+25% on the year before ($1.03B)
Nebulized Tyvaso$586M18%
−0.2% on the year before ($587M)
Remodulin$527M17%
−2.1% on the year before ($538M)
Orenitram$497M16%
+14% on the year before ($434M)
Unituxin$227M7.1%
−5.0% on the year before ($239M)
Adcirca$30M0.9%
+26% on the year before ($23.8M)
Other$24M0.8%
+8.6% on the year before ($22.1M)
Total revenue$3.18B+11%
The company also reports Tyvaso ($1.88B), which group lines above and are not added again.
By region
United States$3.04B95%
+11% on the year before ($2.74B)
Rest-of-World$146M4.6%
+5.8% on the year before ($138M)
Total revenue$3.18B+11%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
For additional detail regarding our commercial products, see Part I, Item 1—Business—Our Commercial Products. Research and Development We are engaged in research and development of new indications and delivery devices for our existing products. We are studying Nebulized Tyvaso in patients with IPF and PPF (the TETON studies). In addition, we are developing a new product to treat PAH, ralinepag. We are also heavily engaged in research and development of organ transplantation-related technologies including xenotransplantation, regenerative medicine, and ex vivo lung perfusion. For additional detail regarding our research and development programs, see Part I, Item 1—Business—Research and Development.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Feb 25, 2026, compared with the one filed Feb 26, 2025. Read the filing
No longer listed (1 heading from the year before)
We may not be able to generate sufficient cash to service or repay our indebtedness, which may have a material adverse effect on our financial position, results of operations, and cash flows.
Legal proceedings (Item 3)
Currently, and from time to time, we are subject to claims in legal proceedings arising in the normal course of business. While we presently believe that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows, or results of operations, legal proceedings are inherently uncertain, and unfavorable rulings could, individually or in the aggregate, have a material adverse effect on our business, financial condition, or operating results.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 52.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.9% on ATS, 25.3% with other brokers), above its 26-week average of 49.4%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (15.5%), SIGMA X2 (11.9%), INTELLIGENT CROSS LLC (11.3%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
When insiders usually buy
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 23, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From United Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know United Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.